Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 4;135(4):393-399.
doi: 10.1097/CM9.0000000000001929.

Interleukins in the treatment of melanoma

Xinyuan Xu  1 , Wei Dai, Chunying Li
Affiliations

Interleukins in the treatment of melanoma

Xinyuan Xu et al. Chin Med J (Engl). .

Abstract

Interleukins (ILs) and associated cytokines serve as the means of communication for immune cells and non-immune cells. The use of ILs in harnessing the immune system to cancer treatment has been a promising approach. ILs not only nurture an environment enabling cancer growth but also simultaneously trigger a productive tumor-directed immune response. These properties of ILs are increasingly being explored as a strategy to improve the outcomes of cancer. Here, we describe recently innovative technological approaches that have been developed to improve the pharmacokinetics, safety, and efficacies of IL-2, 15, 10, and 18 in the treatment of melanoma. Furthermore, the combination of ILs and immune checkpoint inhibition may synergize to reshape the tumor environment, thus yielding better clinical benefits in the future.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Interleukin-based immune control in melanoma. CTLA-4: Anticytotoxic T-lymphocyte-associated protein-4; IFN: Interferon; IL: Interleukin; MHC: Major histocompatibility complex; PD-L1: Programmed death-ligand 1; TCR: T-cell receptor.
See this image and copyright information in PMC

References

    1. Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med 2021; 384:2229–2240. doi: 10.1056/NEJMra2034861. - PubMed
    1. Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 2018; 175:313–326. doi: 10.1016/j.cell.2018.09.035. - PMC - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646–674. doi: 10.1016/j.cell.2011.02.013. - PubMed
    1. Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer 2021; 21:345–359. doi: 10.1038/s41568-021-00347-z. - PMC - PubMed
    1. Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021; 21:481–499. doi: 10.1038/s41568-021-00363-z. - PMC - PubMed